Adial Pharmaceuticals (ADIL) News Today $0.35 0.00 (-0.23%) As of 01:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest UpdateSeptember 5, 2025 | americanbankingnews.comAdial granted a 180 calendar day extension by Nasdaq to regain complianceSeptember 3, 2025 | msn.comAdial Pharmaceuticals Receives 180-Day Extension to Regain Nasdaq Compliance with Minimum Bid Price RequirementSeptember 3, 2025 | quiverquant.comQAdial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price RuleSeptember 3, 2025 | globenewswire.comZelira Therapeutics (OTCMKTS:ZLDAF) vs. Adial Pharmaceuticals (NASDAQ:ADIL) Head to Head ReviewSeptember 3, 2025 | americanbankingnews.comAdial Hails Senate Moves on TrialsAugust 20, 2025 | baystreet.caAdial Pharmaceuticals Applauds U.S. Senate Support for Expanding Clinical Trial Endpoints in Alcohol Use Disorder TreatmentsAugust 20, 2025 | quiverquant.comQAdial Pharmaceuticals expects cash to fund operations into Q2 of 2026August 15, 2025 | msn.comAdial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comAdial Pharmaceuticals Enters New Sales AgreementAugust 9, 2025 | theglobeandmail.comAdial Pharmaceuticals Inc.August 8, 2025 | barrons.comAdial Pharmaceuticals Completes Successful EOP2 FDA MeetingAugust 6, 2025 | globenewswire.comAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing RequirementJuly 16, 2025 | finance.yahoo.comAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing RequirementJuly 16, 2025 | globenewswire.comAdial Pharmaceuticals Files PCT Patent Application to Protect Core ...July 11, 2025 | morningstar.comMAdial Pharmaceuticals Files Update to Provisional Patent ... - NasdaqJuly 11, 2025 | nasdaq.comAdial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045July 9, 2025 | globenewswire.comADIL - Adial Pharmaceuticals Inc News - MorningstarJuly 2, 2025 | morningstar.comMAdial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product SupplyJune 25, 2025 | globenewswire.comAdial Pharmaceuticals, Inc. (ADIL) Stock Price, Quote, News & Analysis | Seeking AlphaJune 24, 2025 | seekingalpha.comAdial Pharmaceuticals prices $3.6 million public offeringJune 18, 2025 | investing.comAdial Pharmaceuticals Announces Pricing of $3.6 Million Public OfferingJune 17, 2025 | finance.yahoo.comAdial Pharmaceuticals Advances Toward Phase 3 Development for AD04June 11, 2025 | finance.yahoo.comAdial Pharmaceuticals Reports First Quarter 2025 Business Update and Financial ResultsMay 17, 2025 | nasdaq.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finanznachrichten.deAdial Pharmaceuticals Receives Development Milestone Payment from Adovate Following Phase 1 Clinical Trial Initiation for Asthma TreatmentMay 15, 2025 | nasdaq.comAdial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comAdial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 StudyMay 13, 2025 | globenewswire.comAdial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug AdministrationMay 9, 2025 | finance.yahoo.comAdial Pharmaceuticals raises $2.75MMay 7, 2025 | bizjournals.comAdial Pharmaceuticals raises $2.75MMay 7, 2025 | bizjournals.comAdial Pharmaceuticals Secures Patent for Novel Treatment of Alcohol and Opioid Disorders Using AD04 in Genetically Identified PatientsMay 3, 2025 | nasdaq.comAdial Pharmaceuticals secures patent for addiction treatmentMay 2, 2025 | investing.com1ADIL : EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent...May 2, 2025 | benzinga.comAdial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross ProceedsMay 2, 2025 | globenewswire.comAdial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use DisordersMay 1, 2025 | globenewswire.comAdial Pharmaceuticals appoints new COO Tony GoodmanMarch 23, 2025 | uk.investing.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business UpdateMarch 4, 2025 | finanznachrichten.deAdial Pharmaceuticals expects cash to fund operations into 2H of 2025March 4, 2025 | markets.businessinsider.comAdial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business UpdateMarch 4, 2025 | globenewswire.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 26, 2025 | finanznachrichten.deAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 25, 2025 | markets.businessinsider.comAdial says FDA feedback confirms proposed strategy to AD04 Phase 3 formulationFebruary 25, 2025 | markets.businessinsider.comAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 25, 2025 | globenewswire.comAdial awarded patent covering genetic approach to alcoholism by USPTOFebruary 19, 2025 | markets.businessinsider.comAdial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug DependenciesFebruary 19, 2025 | globenewswire.comAdial Pharmaceuticals awarded new U.S. patent on genotype-specific treatmentFebruary 12, 2025 | markets.businessinsider.comEXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related DisordersFebruary 12, 2025 | finance.yahoo.comAdial Pharmaceuticals secures new patent for addiction treatmentFebruary 12, 2025 | msn.comAdial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related DisordersFebruary 12, 2025 | globenewswire.com Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADIL Media Mentions By Week ADIL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADIL News Sentiment▼0.690.84▲Average Medical News Sentiment ADIL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADIL Articles This Week▼41▲ADIL Articles Average Week Get the Latest News and Ratings for ADIL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Adial Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Rein Therapeutics News Reviva Pharmaceuticals News Iterum Therapeutics News Kezar Life Sciences News Clearside Biomedical News Aspire Biopharma News CASI Pharmaceuticals News Promis Neurosciences News Tenax Therapeutics News Dare Bioscience News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADIL) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredThe Obscure Korean War Act That Created a $5.39 Billion Passive Income StreamAn obscure Korean War law has just been enacted by the U.S. government... Allowing it to take a heavy hand ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADIL Stock Alerts